[{"id":"08e2ca85-8428-4328-94c8-5d64e49e90df","acronym":"","url":"https://clinicaltrials.gov/study/NCT00893061","created_at":"2021-01-18T03:25:23.407Z","updated_at":"2024-07-02T16:34:25.786Z","phase":"Phase 3","brief_title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","source_id_and_acronym":"NCT00893061","lead_sponsor":"Centre Oscar Lambret","biomarkers":" ER","pipe":" | ","alterations":" PGR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/16/2009","start_date":" 03/16/2009","primary_txt":" Primary completion: 04/04/2012","primary_completion_date":" 04/04/2012","study_txt":" Completion: 11/26/2014","study_completion_date":" 11/26/2014","last_update_posted":"2024-06-14"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2024-07-02T16:34:27.222Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • Torisel (temsirolimus) • letrozole • Inlyta (axitinib) • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-11"},{"id":"343860fb-1c41-454c-a2e5-97b25f553d79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02954874","created_at":"2021-01-18T14:30:57.547Z","updated_at":"2024-07-02T16:34:37.442Z","phase":"Phase 3","brief_title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","source_id_and_acronym":"NCT02954874","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1155","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-07"},{"id":"60bbdfcc-c05d-4873-8c66-614ba38bb554","acronym":"TAILORx","url":"https://clinicaltrials.gov/study/NCT00310180","created_at":"2021-01-18T01:04:07.094Z","updated_at":"2024-07-02T16:34:37.157Z","phase":"Phase 3","brief_title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","source_id_and_acronym":"NCT00310180 - TAILORx","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10273","initiation":"Initiation: 04/07/2006","start_date":" 04/07/2006","primary_txt":" Primary completion: 03/02/2018","primary_completion_date":" 03/02/2018","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2024-06-07"},{"id":"68ed3b37-b467-4c04-902f-70c0e053d74f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02945579","created_at":"2021-01-18T14:27:45.395Z","updated_at":"2024-07-02T16:34:37.622Z","phase":"","brief_title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","source_id_and_acronym":"NCT02945579","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/20/2017","start_date":" 01/20/2017","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-06-06"},{"id":"583d3d4e-954b-4daf-9f41-90e56eda49dd","acronym":"DYNASTY-Breast02","url":"https://clinicaltrials.gov/study/NCT06018337","created_at":"2023-08-30T14:09:02.590Z","updated_at":"2024-07-02T16:34:37.974Z","phase":"Phase 3","brief_title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","source_id_and_acronym":"NCT06018337 - DYNASTY-Breast02","lead_sponsor":"DualityBio Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)"],"overall_status":"Recruiting","enrollment":" Enrollment 532","initiation":"Initiation: 01/18/2024","start_date":" 01/18/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-06-05"},{"id":"7400d1d1-c93a-4e3e-a35d-94aa2105cdee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05378464","created_at":"2022-05-18T13:00:43.972Z","updated_at":"2024-07-02T16:34:38.084Z","phase":"Phase 1","brief_title":"Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine \u0026 Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT05378464","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • PGR • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive","tags":["HER-2 • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp) • pepinemab (VX15)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-05"},{"id":"7804b598-a4ee-4247-b0fd-55fd2504d527","acronym":"","url":"https://clinicaltrials.gov/study/NCT02035813","created_at":"2021-01-18T09:20:22.799Z","updated_at":"2024-07-02T16:34:58.978Z","phase":"Phase 2","brief_title":"DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).","source_id_and_acronym":"NCT02035813","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HR negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HR negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 116","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2024","study_completion_date":" 01/10/2024","last_update_posted":"2024-06-04"},{"id":"0ed50171-eed5-449a-810c-57f1bdbbcb80","acronym":"OFSET","url":"https://clinicaltrials.gov/study/NCT05879926","created_at":"2023-05-30T14:05:14.431Z","updated_at":"2024-07-02T16:34:59.448Z","phase":"Phase 3","brief_title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","source_id_and_acronym":"NCT05879926 - OFSET","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 3960","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 01/01/2032","primary_completion_date":" 01/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2024-06-03"},{"id":"4de118f4-f565-48f1-9ed6-83996e6bbbe2","acronym":"DEBRA","url":"https://clinicaltrials.gov/study/NCT04852887","created_at":"2021-04-21T11:53:33.835Z","updated_at":"2024-07-02T16:34:59.453Z","phase":"Phase 3","brief_title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","source_id_and_acronym":"NCT04852887 - DEBRA","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1670","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2041","study_completion_date":" 07/01/2041","last_update_posted":"2024-06-03"},{"id":"bbd54b62-457a-494d-90d2-1614ae83c172","acronym":"DESTINY-Breast08","url":"https://clinicaltrials.gov/study/NCT04556773","created_at":"2021-01-18T21:46:53.987Z","updated_at":"2024-07-02T16:34:59.971Z","phase":"Phase 1","brief_title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04556773 - DESTINY-Breast08","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR positive • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 11/28/2025","study_completion_date":" 11/28/2025","last_update_posted":"2024-05-30"},{"id":"e073adbc-974d-423b-b408-1f0614b44b3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04584255","created_at":"2021-01-18T21:52:19.886Z","updated_at":"2024-07-02T16:35:00.414Z","phase":"Phase 2","brief_title":"Niraparib + Dostarlimab In BRCA Mutated Breast Cancer","source_id_and_acronym":"NCT04584255","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive • ER positive + HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive • ER positive + HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 07/17/2025","primary_completion_date":" 07/17/2025","study_txt":" Completion: 07/17/2029","study_completion_date":" 07/17/2029","last_update_posted":"2024-05-29"},{"id":"fcf85952-0162-4369-a256-9018f7fa8e95","acronym":"Ice3 Trial","url":"https://clinicaltrials.gov/study/NCT02200705","created_at":"2021-01-18T10:17:27.257Z","updated_at":"2024-07-02T16:35:00.462Z","phase":"","brief_title":"Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial","source_id_and_acronym":"NCT02200705 - Ice3 Trial","lead_sponsor":"IceCure Medical Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 03/17/2024","primary_completion_date":" 03/17/2024","study_txt":" Completion: 05/26/2024","study_completion_date":" 05/26/2024","last_update_posted":"2024-05-29"},{"id":"d91fc014-de44-430c-a6db-ad9db38dc541","acronym":"","url":"https://clinicaltrials.gov/study/NCT03707340","created_at":"2021-01-18T18:10:32.935Z","updated_at":"2024-07-02T16:35:00.886Z","phase":"","brief_title":"A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors","source_id_and_acronym":"NCT03707340","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 09/14/2018","start_date":" 09/14/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-27"},{"id":"b1021c14-5399-4865-b4e3-db5fb8024093","acronym":"LYNK-002","url":"https://clinicaltrials.gov/study/NCT03742895","created_at":"2021-01-18T18:19:59.379Z","updated_at":"2024-07-02T16:35:01.367Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","source_id_and_acronym":"NCT03742895 - LYNK-002","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PGR positive • BRCA mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PGR positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-23"},{"id":"3d2180e8-cd22-4ae0-8a62-1128eb18f094","acronym":"","url":"https://clinicaltrials.gov/study/NCT06075758","created_at":"2023-10-10T14:12:09.909Z","updated_at":"2024-07-02T16:35:02.287Z","phase":"","brief_title":"A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT06075758","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-21"},{"id":"c1457e9f-dd13-410b-9043-e8e505ad84f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03671330","created_at":"2021-01-18T18:00:35.562Z","updated_at":"2024-07-02T16:35:02.489Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","source_id_and_acronym":"NCT03671330","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 327","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 04/25/2022","primary_completion_date":" 04/25/2022","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2024-05-21"},{"id":"3f558519-49f6-41cf-a5ae-3622a67f25d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04614194","created_at":"2021-01-19T20:33:11.525Z","updated_at":"2024-07-02T16:35:02.537Z","phase":"Phase 2","brief_title":"Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib","source_id_and_acronym":"NCT04614194","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" HER-2 • ER • PGR • CD8","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive","tags":["HER-2 • ER • PGR • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2028","study_completion_date":" 04/15/2028","last_update_posted":"2024-05-20"},{"id":"c32f89f3-a298-4176-84bb-cec4e2a46e3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02398773","created_at":"2021-01-18T11:26:39.322Z","updated_at":"2024-07-02T16:35:02.895Z","phase":"Phase 2","brief_title":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","source_id_and_acronym":"NCT02398773","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER negative • PGR positive • PGR negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR positive • PGR negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 05/04/2016","start_date":" 05/04/2016","primary_txt":" Primary completion: 04/04/2025","primary_completion_date":" 04/04/2025","study_txt":" Completion: 04/04/2025","study_completion_date":" 04/04/2025","last_update_posted":"2024-05-17"},{"id":"0c41a98f-8388-45ac-a5de-f20667e62781","acronym":"","url":"https://clinicaltrials.gov/study/NCT01839838","created_at":"2021-01-18T08:11:39.785Z","updated_at":"2024-07-02T16:35:03.208Z","phase":"","brief_title":"APBI Proton Feasibility and Phase II Study","source_id_and_acronym":"NCT01839838","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 04/22/2013","start_date":" 04/22/2013","primary_txt":" Primary completion: 12/23/2022","primary_completion_date":" 12/23/2022","study_txt":" Completion: 12/23/2022","study_completion_date":" 12/23/2022","last_update_posted":"2024-05-16"},{"id":"80befaa4-53a0-4489-baa2-338cc2dfb32a","acronym":"TIBET","url":"https://clinicaltrials.gov/study/NCT04489173","created_at":"2021-01-18T21:34:16.480Z","updated_at":"2024-07-02T16:35:03.947Z","phase":"Phase 2","brief_title":"TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT04489173 - TIBET","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 01/08/2024","primary_completion_date":" 01/08/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-14"},{"id":"86fab96d-2e9b-46db-bfb5-1b9bf74ce73a","acronym":"AIPAC-003","url":"https://clinicaltrials.gov/study/NCT05747794","created_at":"2023-02-28T13:01:27.736Z","updated_at":"2024-07-02T16:35:04.109Z","phase":"Phase 2/3","brief_title":"Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy","source_id_and_acronym":"NCT05747794 - AIPAC-003","lead_sponsor":"Immutep S.A.S.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HR negative • PGR positive","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HR negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ImmuFact (eftilagimod alpha)"],"overall_status":"Recruiting","enrollment":" Enrollment 849","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-05-13"},{"id":"b5da7b4a-4908-4f45-9515-2de24f2647c5","acronym":"OlympiA","url":"https://clinicaltrials.gov/study/NCT02032823","created_at":"2021-01-18T09:19:21.347Z","updated_at":"2024-07-02T16:35:04.147Z","phase":"Phase 3","brief_title":"Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer","source_id_and_acronym":"NCT02032823 - OlympiA","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive","tags":["HER-2 • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1836","initiation":"Initiation: 04/22/2014","start_date":" 04/22/2014","primary_txt":" Primary completion: 03/27/2020","primary_completion_date":" 03/27/2020","study_txt":" Completion: 05/28/2029","study_completion_date":" 05/28/2029","last_update_posted":"2024-05-13"},{"id":"1694a214-0630-452e-9847-de4cf48eff13","acronym":"","url":"https://clinicaltrials.gov/study/NCT02926729","created_at":"2021-01-18T14:22:31.553Z","updated_at":"2024-07-02T16:35:04.817Z","phase":"","brief_title":"Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy","source_id_and_acronym":"NCT02926729","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • ER negative • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative • PGR positive • PGR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 07/17/2019","start_date":" 07/17/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-09"}]